Elocom

Leaflet attached to the packaging: information for the user

Warning!

The leaflet should be kept. Information on the immediate packaging in a foreign language.

Elocom (Elocon)

1 mg/g, solution for the skin
Mometasone furoate
Elocom and Elocon are different trade names for the same drug.

You should carefully read the contents of the leaflet before using the medicine, as it contains important information for the patient.

• You should keep this leaflet, so that you can read it again if you need to.
• If you have any doubts, you should consult a doctor or pharmacist.
• This medicine has been prescribed specifically for you. Do not pass it on to others. The medicine may harm them, even if their symptoms are the same as yours.
• If you experience any side effects, including those not listed in this leaflet, you should tell your doctor, pharmacist, or nurse. See section 4.

Table of contents of the leaflet

• 1. What is Elocom and what is it used for
• 2. Important information before using Elocom
• 3. How to use Elocom
• 4. Possible side effects
• 5. How to store Elocom
• 6. Contents of the packaging and other information

1. What is Elocom and what is it used for

Elocom solution for the skin contains the active substance mometasone furoate.
Mometasone furoate is a synthetic corticosteroid; when used locally, it has anti-inflammatory, antipruritic, and vasoconstrictive effects.
Elocom solution for the skin is indicated for the relief of inflammatory and pruritic symptoms of scalp disorders, such as psoriasis and atopic dermatitis, which are responsive to corticosteroid treatment.

2. Important information before using Elocom

When not to use Elocom:

• if you are allergic to mometasone furoate, other corticosteroids, or any of the other ingredients of this medicine (listed in section 6),
• in acne vulgaris,
• in rosacea,
• in skin atrophy,
• in bacterial infections (e.g., impetigo, pyoderma), viral infections (e.g., herpes simplex, chickenpox, and shingles), parasitic and fungal skin infections (e.g., caused by dermatophytes or yeast),
• in post-vaccination reactions,
• in skin tuberculosis,
• on syphilitic skin lesions,
• in anal and genital itching,
• in diaper rash,
• on damaged and ulcerated skin.

Warnings and precautions

Before starting to use Elocom, you should discuss it with your doctor or pharmacist.
If you experience any symptoms of irritation or allergy after using the medicine, you should contact your doctor immediately.
If an infection occurs, your doctor will prescribe appropriate antibacterial or antifungal treatment. If there is no rapid and positive response to treatment, you should stop using the corticosteroid until the infection is healed.
Due to the increased risk of systemic side effects of corticosteroids, you should avoid using Elocom on large areas of skin, under dressings, for a long time, and on the skin of the face and in skin folds, as well as in children. If it is necessary to apply the medicine to the face, treatment should not last more than 5 days.
Any side effects reported after using systemic corticosteroids, including adrenal suppression, may also occur with topical corticosteroids, especially in infants and children.
In children, due to their larger skin surface area to body mass ratio compared to adults, there is a greater likelihood of systemic side effects of corticosteroids, such as disruption of the hypothalamic-pituitary-adrenal axis and Cushing's syndrome.
The medicine should not be used on skin covered with a diaper, as it may act like a dressing and increase the percutaneous absorption of mometasone furoate.
You should use the smallest effective dose of the medicine that allows for the relief of symptoms, especially in children. Long-term treatment with corticosteroids may affect the growth and development of children.
Elocom is not intended for ophthalmic use (including the area around the eyes) due to the very rare risk of developing glaucoma or subcapsular cataract.
Patients with psoriasis should use the medicine with special caution.
Using the medicine in psoriasis may cause the disease to recur due to the development of tolerance, the occurrence of generalized pustular psoriasis, and general toxic effects related to skin barrier disruption.
As with other potent topical corticosteroids, you should avoid sudden discontinuation of treatment. After sudden withdrawal of the medicine, severe redness, burning, and stinging (so-called "rebound effect") may occur. In such cases, you should contact your doctor.
Elocom, like other medicines containing corticosteroids, may change the appearance of some skin lesions, making it difficult for the doctor to diagnose, and may also delay healing.
You should consult your doctor, even if the above warnings refer to situations that have occurred in the past.
If you experience blurred vision or other vision disturbances, you should contact your doctor.

Elocom and other medicines

No data available.
You should tell your doctor or pharmacist about all medicines you are currently taking or have recently taken, as well as any medicines you plan to take.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant, or plan to have a child, you should consult your doctor or pharmacist before using this medicine.

Pregnancy

The safety of Elocom during pregnancy has not been established.
Elocom can be used during pregnancy only if, in the doctor's opinion, the benefit to the mother outweighs the potential risk to the mother and fetus. However, the medicine should not be used on large areas of skin and for a long time. Animal studies have shown that corticosteroids may harm the fetus.

Breastfeeding

It is not known whether topical corticosteroids are absorbed through the skin into the body in sufficient amounts to pass into breast milk.
Elocom can be used by breastfeeding women only if the doctor decides to do so after careful consideration of the risk of side effects in children compared to the benefits of treatment for the mother. If the doctor considers long-term therapy necessary, breastfeeding should be discontinued.

Driving and using machines

Elocom does not affect the ability to drive and use machines.

Elocom solution for the skin contains propylene glycol (E 1520)

Propylene glycol (E 1520) may cause skin irritation.

3. How to use Elocom

This medicine should always be used as directed by your doctor. If you are unsure, you should consult your doctor or pharmacist.
The medicine is intended for topical use on the skin.
Usually, a few drops of the solution are applied once a day to the affected areas of the scalp. Gently and thoroughly massage until the solution disappears.
If you feel that the effect of the medicine is too strong or too weak, you should consult your doctor.

Use in children

Elocom should be used with caution in children over 2 years of age, although the safety and efficacy of Elocom have not been studied for more than 3 weeks.
There is insufficient data on the use of the medicine in children under 2 years of age.
You should use the smallest effective dose of the medicine that allows for the relief of symptoms.
Long-term treatment with corticosteroids may affect the growth and development of children.

Using a higher dose of Elocom than recommended

No cases of overdose have been reported so far.
Prolonged topical use of corticosteroids may lead to suppression of the hypothalamic-pituitary-adrenal axis and, consequently, to adrenal insufficiency.
In case of overdose, the doctor will provide appropriate symptomatic treatment and supportive treatment. Acute symptoms of corticosteroid overdose are usually reversible. In case of chronic poisoning, the doctor will recommend gradual withdrawal of the medicine.
If you have ingested the medicine, you should contact your doctor immediately.

Missing a dose of Elocom

You should not use a double dose to make up for a missed dose.

4. Possible side effects

Like all medicines, Elocom can cause side effects, although not everybody gets them.
The following side effects have been observed during the use of topical corticosteroids:

• Very rare (occurring in less than 1 in 10,000 patients): folliculitis, burning sensation, pruritus.
• Frequency not known (cannot be estimated from the available data): infections, furuncles, paresthesia, contact dermatitis, hypopigmentation, hypertrichosis, striae, acneiform eruptions, skin atrophy, pain at the application site, reactions at the application site, blurred vision.

After using the medicine on large areas of skin for a long time, especially with occlusive dressings, systemic absorption of the medicine has been observed.
The following side effects have been observed during the topical use of corticosteroids: dry skin, skin irritation, dermatitis, perioral dermatitis, maceration, folliculitis, and telangiectasias.

Reporting side effects

If you experience any side effects, including those not listed in this leaflet, you should tell your doctor, pharmacist, or nurse. Side effects can be reported directly to the Department of Drug Safety Monitoring of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, Tel.: +48 22 49 21 301, Fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl
By reporting side effects, you can help provide more information on the safety of this medicine.

5. How to store Elocom

The medicine should be stored out of sight and reach of children.
Store at a temperature below 25°C. Do not store in the refrigerator. Do not freeze.
Do not use damaged or opened packaging.
Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the month stated.
Shelf life after first opening the bottle: 3 months.
Medicines should not be disposed of via wastewater or household waste. You should ask your pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.

6. Contents of the packaging and other information

What Elocom contains

• The active substance of the medicine is mometasone furoate. Each gram of solution contains 1 mg of mometasone furoate.
• The other ingredients are: isopropyl alcohol, propylene glycol (E 1520), hydroxypropyl cellulose, sodium dihydrogen phosphate dihydrate, diluted phosphoric acid, purified water. This medicine contains 300 mg of propylene glycol (E 1520) per milliliter of solution, which corresponds to 6 g of propylene glycol (E 1520) per unit (20 ml bottle).

What Elocom looks like and contents of the packaging

Elocom is a solution for the skin.
Packaging of the medicine
A plastic bottle containing 20 ml of solution, placed in a cardboard box.
For more detailed information, you should contact the marketing authorization holder or parallel importer.

Marketing authorization holder in Latvia, the country of export:

N.V. Organon
Kloosterstraat 6
5349 AB Oss
Netherlands

Manufacturer:

Organon Heist bv
Industriepark 30
2220 Heist-op-den-Berg
Belgium

Parallel importer:

Delfarma Sp. z o.o.
ul. Św. Teresy od Dzieciątka Jezus 111
91-222 Łódź

Repackaged by:

Delfarma Sp. z o.o.
ul. Św. Teresy od Dzieciątka Jezus 111
91-222 Łódź
Marketing authorization number in Latvia, the country of export: 99-1029

Parallel import authorization number: 6/25

Date of leaflet approval: 13.01.2025

[Information about the trademark]